Evidence map›Paper›PMID 35380100›Full record

ArticleEmerging microbes & infections2022

Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.

Jun Cai, Juan Yang, Xiaowei Deng, Cheng Peng, Xinhua Chen, Qianhui Wu, Hengcong Liu, Juanjuan Zhang, Wen Zheng, Junyi Zou and 3 more

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Jun CaiSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Juan YangSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Xiaowei DengSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Cheng PengSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Xinhua ChenSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Qianhui WuSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Hengcong LiuSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Juanjuan ZhangSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Wen ZhengSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Junyi ZouSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Zeyao ZhaoSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Marco AjelliLaboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA.
Hongjie YuSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.
Fudan University · CNIndiana University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection causes most cases of severe illness and fatality in older age groups. Over 92% of the Chinese population aged ≥12 years has been fully vaccinated against COVID-19 (albeit with vaccines developed against historical lineages). At the end of October 2021, the vaccination programme has been extended to children aged 3-11 years. Here, we aim to assess whether, in this vaccination landscape, the importation of Delta variant infections could shift COVID-19 burden from adults to children. We developed an age-structured susceptible-infectious-removed model of SARS-CoV-2 transmission to simulate epidemics triggered by the importation of Delta variant infections and project the age-specific incidence of SARS-CoV-2 infections, cases, hospitalizations, intensive care unit admissions, and deaths. In the context of the vaccination programme targeting individuals aged ≥12 years, and in the absence of non-pharmaceutical interventions, the importation of Delta variant infections could have led to widespread transmission and substantial disease burden in mainland China, even with vaccination coverage as high as 89% across the eligible age groups. Extending the vaccination roll-out to include children aged 3-11 years (as it was the case since the end of October 2021) is estimated to dramatically decrease the burden of symptomatic infections and hospitalizations within this age group (39% and 68%, respectively, when considering a vaccination coverage of 87%), but would have a low impact on protecting infants. Our findings highlight the importance of including children among the target population and the need to strengthen vaccination efforts by increasing vaccine effectiveness.

Indexed as

COVID-19VaccinesAdultAgedChildChinaCOVID-19 VaccinesHumansInfantSARS-CoV-2VaccinationCOVID-19 VaccinesVaccineschildrenChinaDelta variantNovel coronavirus disease 2019transition of disease burdenvaccination

Identifiers

PMID35380100
PMCPMC9045766
OpenAlexW4224930246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.